| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN (NCT06994845) | Novartis Pharmaceuticals | 2025-11-27 |
| A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (NCT07174063) | Novartis Pharmaceuticals | 2025-11-26 |
| Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia (NCT07034690) | Novartis Pharmaceuticals | 2025-11-26 |
| Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (NCT07261631) | Novartis Pharmaceuticals | 2025-11-24 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease (NCT07235059) | Novartis Pharmaceuticals | 2025-11-20 |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (NCT07225504) | Novartis Pharmaceuticals | 2025-11-11 |
| Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT07220577) | Novartis Pharmaceuticals | 2025-11-10 |
| A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease (NCT07203001) | Novartis Pharmaceuticals | 2025-11-03 |
| Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients (NCT06934967) | Novartis Pharmaceuticals | 2025-10-28 |
| A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation (NCT07217067) | Novartis Pharmaceuticals | 2025-10-28 |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (NCT07006727) | Novartis Pharmaceuticals | 2025-10-16 |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (NCT07206056) | Novartis Pharmaceuticals | 2025-10-15 |
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) (NCT06997588) | Novartis Pharmaceuticals | 2025-10-09 |
| Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (NCT07102628) | Novartis Pharmaceuticals | 2025-10-03 |
| A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A. (NCT07140614) | Novartis Pharmaceuticals | 2025-09-30 |
| Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients (NCT07142265) | Novartis Pharmaceuticals | 2025-09-30 |
| Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). (NCT06751238) | Novartis Pharmaceuticals | 2025-09-24 |
| Fabhalta Capsules Specified Drug-use Survey (NCT07156149) | Novartis Pharmaceuticals | 2025-09-17 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (NCT06894511) | Novartis Pharmaceuticals | 2025-09-11 |
| RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia (NCT06797531) | Novartis Pharmaceuticals | 2025-08-27 |
| Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) (NCT06770543) | Novartis Pharmaceuticals | 2025-08-13 |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease (NCT07094516) | Novartis Pharmaceuticals | 2025-08-07 |
| Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer (NCT07093801) | Novartis Pharmaceuticals | 2025-07-30 |
| NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice (NCT07036718) | Novartis Pharmaceuticals | 2025-07-29 |
| Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. (NCT06858319) | Novartis Pharmaceuticals | 2025-07-28 |
| A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (NCT07032272) | Novartis Pharmaceuticals | 2025-07-23 |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (NCT06868212) | Novartis Pharmaceuticals | 2025-07-11 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT07047118) | Novartis Pharmaceuticals | 2025-07-03 |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (NCT06846281) | Novartis Pharmaceuticals | 2025-06-23 |
| A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease (NCT07048197) | Novartis Pharmaceuticals | 2025-06-20 |
| Inclisiran Effectiveness in China: a Pragmatic Randomized Trial (NCT06941792) | Novartis Pharmaceuticals | 2025-06-17 |
| Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study (NCT06958315) | Novartis Pharmaceuticals | 2025-06-16 |
| An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis (NCT07029555) | Novartis Pharmaceuticals | 2025-06-12 |
| A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China (NCT06931691) | Novartis Pharmaceuticals | 2025-06-10 |
| A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy (NCT07403214) | Novartis Pharmaceuticals | 2025-06-04 |
| DFT383 in Pediatric Participants With Nephropathic Cystinosis (NCT06910813) | Novartis Pharmaceuticals | 2025-06-02 |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (NCT06784752) | Novartis Pharmaceuticals | 2025-05-30 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria (NCT06865651) | Novartis Pharmaceuticals | 2025-05-22 |
| Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) (NCT06711887) | Novartis Pharmaceuticals | 2025-05-19 |
| Pelacarsen Roll-over Extension Program (NCT06875973) | Novartis Pharmaceuticals | 2025-05-19 |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis (NCT06947993) | Novartis Pharmaceuticals | 2025-05-16 |
| Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (NCT06431750) | Novartis Pharmaceuticals | 2025-04-30 |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD (NCT06813911) | Novartis Pharmaceuticals | 2025-04-30 |
| A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. (NCT06632600) | Novartis Pharmaceuticals | 2025-04-28 |
| Post Marketing Study on Pluvicto in Korea (NCT06514521) | Novartis Pharmaceuticals | 2025-04-18 |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia (NCT06858332) | Novartis Pharmaceuticals | 2025-04-15 |
| Home Reported Outcomes in C3G Study (NCT07029542) | Novartis Pharmaceuticals | 2025-04-07 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors (NCT06726148) | Novartis Pharmaceuticals | 2025-04-03 |
| Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. (NCT06905288) | Novartis Pharmaceuticals | 2025-04-02 |
| Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry (NCT06903234) | Novartis Pharmaceuticals | 2025-03-31 |
| Ilaris NIS in Korea (NCT06838143) | Novartis Pharmaceuticals | 2025-03-29 |
| A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients (NCT06857955) | Novartis Pharmaceuticals | 2025-03-26 |
| RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) (NCT06684964) | Novartis Pharmaceuticals | 2025-03-24 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (NCT06840392) | Novartis Pharmaceuticals | 2025-03-20 |
| Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants (NCT05541159) | Novartis Pharmaceuticals | 2025-03-19 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA (NCT06868290) | Novartis Pharmaceuticals | 2025-03-13 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab (NCT06869785) | Novartis Pharmaceuticals | 2025-03-13 |
| Long-term Follow up Local Registry Study of Kymriah in South Korea (NCT06785818) | Novartis Pharmaceuticals | 2025-03-12 |
| Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab. (NCT06785675) | Novartis Pharmaceuticals | 2025-03-10 |
| A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse (NCT07743281) | Novartis Pharmaceuticals | 2025-03-10 |
| Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia (NCT06785779) | Novartis Pharmaceuticals | 2025-03-10 |
| Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants (NCT05490030) | Novartis Pharmaceuticals | 2025-03-06 |
| A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US (NCT06952426) | Novartis Pharmaceuticals | 2025-03-04 |
| Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia (NCT06597006) | Novartis Pharmaceuticals | 2025-02-28 |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (NCT06780670) | Novartis Pharmaceuticals | 2025-02-27 |
| A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients (NCT07760714) | Novartis Pharmaceuticals | 2025-02-26 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis (NCT06617793) | Novartis Pharmaceuticals | 2025-02-24 |
| Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN (NCT06797518) | Novartis Pharmaceuticals | 2025-02-21 |
| A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence (NCT06830720) | Novartis Pharmaceuticals | 2025-02-20 |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. (NCT06514534) | Novartis Pharmaceuticals | 2025-02-18 |
| LATAM LOWERS LDL-C (NCT06501443) | Novartis Pharmaceuticals | 2025-02-11 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (NCT06744920) | Novartis Pharmaceuticals | 2025-02-07 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) (NCT06799000) | Novartis Pharmaceuticals | 2025-01-31 |
| Modifying PEST for Psoriatic Arthritis Screening (NCT06382051) | Novartis Pharmaceuticals | 2025-01-23 |
| A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients (NCT07409636) | Novartis Pharmaceuticals | 2025-01-23 |
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants (NCT05367401) | Novartis Pharmaceuticals | 2024-12-20 |
| Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure) (NCT06659393) | Novartis Pharmaceuticals | 2024-12-19 |
| Phase 2 Study of Rapcabtagene Autoleucel in Myositis (NCT06665256) | Novartis Pharmaceuticals | 2024-12-17 |
| Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) (NCT06675864) | Novartis Pharmaceuticals | 2024-12-12 |
| Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. (NCT05959304) | Novartis Pharmaceuticals | 2024-12-11 |
| Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study (NCT06486779) | Novartis Pharmaceuticals | 2024-12-10 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia (NCT06597019) | Novartis Pharmaceuticals | 2024-12-09 |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (NCT06427811) | Novartis Pharmaceuticals | 2024-11-28 |
| ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS (NCT06733922) | Novartis Pharmaceuticals | 2024-11-27 |
| Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases (NCT06411639) | Novartis Pharmaceuticals | 2024-11-25 |
| Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (NCT06668324) | Novartis Pharmaceuticals | 2024-11-15 |
| A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT06386419) | Novartis Pharmaceuticals | 2024-11-12 |
| A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (NCT06531499) | Novartis Pharmaceuticals | 2024-11-11 |
| A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies (NCT07378943) | Novartis Pharmaceuticals | 2024-11-06 |
| A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis (NCT06551519) | Novartis Pharmaceuticals | 2024-10-28 |
| A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients (NCT07566988) | Novartis Pharmaceuticals | 2024-10-25 |
| A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) (NCT06649110) | Novartis Pharmaceuticals | 2024-10-24 |
| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (NCT06439082) | Novartis Pharmaceuticals | 2024-10-24 |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) (NCT06643481) | Novartis Pharmaceuticals | 2024-10-17 |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (NCT06562192) | Novartis Pharmaceuticals | 2024-10-15 |
| A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation (NCT06625333) | Novartis Pharmaceuticals | 2024-10-11 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis (NCT06470048) | Novartis Pharmaceuticals | 2024-10-09 |
| An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (NCT06335979) | Novartis Pharmaceuticals | 2024-10-08 |
| Specified Drug-use Surveillance of Fabhalta Capsules (NCT06606314) | Novartis Pharmaceuticals | 2024-09-18 |
| A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients (NCT07477756) | Novartis Pharmaceuticals | 2024-09-04 |